Genprex, Inc.
GNPX$5M
Micro CapNASDAQPharmaceutical Preparations🇺🇸North AmericaAUSTIN
Drugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Feb 15, 2026
7dData is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply
Market Overview
Stock performance and market intelligence
Catalyst Timeline
1 upcoming, 0 past
Phase 2Next
quaratusugene ozeplasmid Phase 2 Results Expected
February 2026~quaratusugene ozeplasmid62
Primary completion for quaratusugene ozeplasmid trial (NCT05703971) in Small Cell Lung Cancer Extensive Stage
SourceAI Predictions & Institutional Flow
Machine learning insights and smart money movement
FDA Submissions
Pending NDA/BLA submissions with predicted PDUFA dates
Drug Pipeline
Clinical development programs and drug candidates
Drug Pipeline
| Drug Name | Phase | Indication | Designations |
|---|---|---|---|
quaratusugene ozeplasmid | Phase 2 | Carcinoma, Non-Small Cell Lung | - |
Regulatory & News
Approvals, filings, and latest developments
Regulatory Approvals
GNPX News